Anti-CDK6, clone 2J3 ZooMAb� Rb mono

Application

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CDK6 in HeLa cell lysate.Affinity Binding Assay: A representative lot of this antibody bound CDK6 peptide with a KD value of 2.8 x 10-6 in an affinity binding assay.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CDK6 in HeLa, A431, HUVEC, and NIH 3T3 cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CDK6 in human kidney and human testis tissue sections.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-CDK6, clone 2J3 ZooMAb, Cat. No. ZRB1490, is a recombinant Rabbit monoclonal antibody that specifically targets CDK6 and is tested for use in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry (Paraffin), Western Blotting.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

KLH-conjugated linear peptide corresponding to 21 amino acids from the C-terminal region of human CDK6.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

0.3 mg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 2J3 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects CDK6. It targets an epitope within 21 amino acids from the C-terminal region.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

DNA polymerase beta (UniProt: P06746; also known as EC:2.7.7.7, DNAP, Polβ, DNA pol beta) is encoded by the POLB gene (Gene ID: 5423) in human. Pol β is a member of the X family of DNA polymerases. It plays a role in the base excision repair pathway that is essential to cleanse the genome of simple base lesions and abasic sites that arise in DNA from spontaneous base loss. Polβ is cytoplasmic under normal conditions, but it translocates to the nucleus following DNA damage where it associates with AP endonuclease 1 (Apex) to carry out DNA repair. It possesses two catalytic activities: DNA polymerase activity and dRP lyase activity. The active site for each of these activities is located on a distinct domain of the protein: 31 kDa polymerase domain and amino-terminal 8 kDa lyase domain. Polβ does not have proofreading activity; however, its accuracy in vitro results exclusively from the nucleotide selectivity of this enzyme. Aberrant Polβ overexpression results in an increased rate of spontaneous mutagenesis and a highly mutagenic tolerance phenotype and about thirty percent of all tumors are reported to harbor mutations in the POLB gene. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Beard WA., et al. (2006). Methods Enzymol. 408; 91-107).